Aclaris Therapeutics's quarterly market cap
declined
from Sep. 2023 ($480.08 Mil) to Dec. 2023 ($75.08 Mil) but then
increased
from Dec. 2023 ($75.08 Mil) to Mar. 2024 ($89.06 Mil).
Aclaris Therapeutics's annual market cap
increased
from Dec. 2021 ($880.71 Mil) to Dec. 2022 ($992.86 Mil) but then
declined
from Dec. 2022 ($992.86 Mil) to Dec. 2023 ($75.08 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aclaris Therapeutics's Enterprise Value for Today is $-39.58 Mil.
Aclaris Therapeutics Market Cap Historical Data
The historical data trend for Aclaris Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aclaris Therapeutics's Market Cap
For the Diagnostics & Research subindustry, Aclaris Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Market Cap falls into.
Aclaris Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aclaris Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (LTS:0H8T) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aclaris Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Aclaris Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Aclaris Therapeutics (LTS:0H8T) Business Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0H8T has been successfully added to your 